Instructions for Lydase (Hyaluronidase) lyophilisate for solution preparation
English product name
Lydase-M
Release Form Hyaluronidase
lyophilizate d/r-fit d/injection and local approx. 1280 IU: amp. 5, 10, 20, 25, 50, 60, 100, 120, 200 units, fl. 5 or 10 pcs, with or without solvent
Description Lydase
Lyophilizate for injection preparation and local application 1 fl
hyaluronidase
ATC codes Hyaluronidase
B06AA03 Hyaluronidase
Clinical-pharmacological groups / Group affiliation Lydase
Preparation having proteolytic activity
Active substance
hyaluronidase
Pharmaco-therapeutic group Lydase
Enzyme agent
Pharmacological effect Hyaluronidase
A seed-derived enzyme from the seeds of cattle. Cleaves the main component of the interspecific substance of the connective tissue - hyaluronic acid (mucopolysaccharide, which includes acetylglucosamine and glucuronic acid, is a cementing substance of the connective tissue). Hyaluronidase causes hyaluronic acid to decay to glucosamine and glucuric acid and thus reduces its viscosity. The invention makes it possible to increase tissue and vascular permeability and to ease the diffusion of liquids in the intertissue space. Reduces swelling of the tissue, softens and flattens the scars, increases the volume of movements in the joints, reduces contracture and prevents their formation.
In parenteral administration (n/c and v/m), a single dose is 1280 IU.
Hyaluronidase has a reversible effect: when the concentration of hyaluronic acid decreases, the viscosity of the hyaluronic acid is restored.
In parenteral administration (n/c and v/m), a single dose is 1280 IU.
Duration of action in / for the introduction - up to 48 hours.
In parenteral administration (n/c and v/m), a single dose is 1280 IU.
Testimony
Burn, traumatic, post-surgery scars; long-term non-healing ulcers (including radiation); Dupuytren contracture; stiff joints mobility, joint contracture (after inflammatory processes, injuries), osteoarthrosis, ankylosing spondyloarthritis, severe diseases of the lumbar discs; chronic tendovaginitis, scleroderma (skin manifestations), soft tissue hematoma surface localization; preparation for skin-plastic operations on scar contractions.
In parenteral administration (n/c and v/m), a single dose is 64 UE.
Method of use, course and dosage Lydase
In parenteral administration (n/c and v/m), a single dose is 1280 IU.
For inhalation, retrobulbar administration and for application to the conjunctiva, the dose is set individually, depending on the indications.
Special Instructions Hyaluronidase
The solution should not be injected through a catheter into which solutions containing cations were previously introduced.
Before starting treatment, it is advisable to carry out a test with b/c introduction of hyaluronidase.
Do not inject into the areas of infectious inflammation and tumour.
- Nosology Hyaluronidase (ICD codes)
- A15
- Respiratory tuberculosis confirmed bacteriologically and histologically
- G54
- Lesions of the nerve spine and plexus
- H17
- Scarring and clouding of the cornea
- H35.0
- Background retinopathy and retinal vascular changes
- H36.0
- Diabetic retinopathy
- H43.1
- Vitreous hemorrhage
- L90.5
- Scarring and skin fibrosis
- L91
- Hypertrophic changes of the skin
- L98.4
- Chronic skin ulcer not classified in other categories
- M15
- Polyarthrosis
- M24.5
- Joint contracture
- M25.6
- Joint stiffness not classified in other headings
- M34
- Systemic sclerosis
- M45
- Ankylosing spondylitis
- M47
- Spondylosis
- M51.9
- Intervertebral disc lesion unspecified
- M65
- Synovitis and tenosinovites
- M72.0
- Brass fascial fibromatosis [Dupuytren]
- M79.2
- Neuralgia and Neuritis Unspecified
- T14.0
- Superficial injury of an unspecified area of the body (including abrasion, bruising, bruising, hematoma, bite of a non-venomous insect)
- Z51.4
- Preparatory procedures for follow-up treatment or examination not classified elsewhere
